Drug
Acasunlimab
Acasunlimab: highest development phase Phase 3, developed by Genmab. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Genmab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Acasunlimab NCT06635824 | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC |
| Acasunlimab NCT05117242 | Phase 2 | Non Small Cell Lung Cancer Metastatic |
| Acasunlimab NCT03917381 | Phase 1/2 | Solid Tumors |
| Acasunlimab NCT04937153 | Phase 1 | Solid Tumor |
Latest
Follow Acasunlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.